Genotype 1
(n=416) |
PEG-IFN alfa-2a
(n=254) |
PEG-IFN alfa-2b
(n=162) |
P* |
| SVR (n=262), n (%) |
254 (61.1) |
162 (38.9) |
0.76 |
| Age, n (%) |
| ≤50 years (n=212) |
88/133 (66.2) |
61//79 (77.2) |
0.12 |
| >50 years (n=204) |
70/121 (57.9) |
43/83 (51.8) |
0.47 |
| HCV RNA (IU/mL), n (%) |
|
|
|
| ≤7×105(n=149) |
76/117 (65.0) |
46/67 (68.7) |
0.63 |
| >7×105(n=232) |
82/137 (59.9) |
58/95 (61.1) |
0.89 |
| Liver fibrosis, n (%)† |
| F 0-2 (n=80) |
48/62 (77.4) |
11/18 (61.1) |
0.22 |
| F 3-4 (n=49) |
18/43 (41.9) |
4/6 (66.7) |
0.39 |
| Genotype 2/3 |
PEG-IFN alfa-2a |
PEG-IFN alfa-2b |
0.29 |
| (n=235) |
(n=141) |
(n=94) |
|
| SVR (n=187), n (%) |
112 (79.4) |
75 (79.8) |
1.00 |
| Age, n (%) |
| ≤50 years (n=125) |
71/80 (88.8) |
38/45 (84.4) |
0.58 |
| >50 years(n=110) |
41/61 (67.2) |
37/49 (75.5) |
0.40 |
| HCV RNA (IU/mL), n (%) |
| ≤7×105 (n=137) |
63/81(77.8) |
49/56 (87.5) |
0.18 |
| >7×105 (n=98) |
49/60 (81.7) |
26/38 (68.4) |
0.15 |
| Liver fibrosis, n (%)‡ |
| F 0-2 (n=59) |
42/51 (82.4) |
7/8 (87.5) |
1.00 |
| F 3-4 (n=15) |
7/10 (70.0) |
3/5 (60.0) |
1.00 |
Abbreviation
HCV- Hepatitis C Virus; PEG-IFN- Peginterferon; SVR-Sustained Virologic Response
† and ‡ Data were available in 129 and 74 patients, respectively |
